Somatuline Depot 60 mg in 0.2 mL Prefilled Syringe
RxNorm 749813
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 749813 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Somatuline Depot 60 mg in 0.2 mL Prefilled Syringe.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDPrescribable
Semantic Branded Drug (SBD):
0.2 mL lanreotide 300 mg/ML Prefilled Syringe [Somatuline]
(Atom ID: 2761387)
SYPrescribable
Synonym (SY):
0.2 mL Somatuline 300 mg/ML (as lanreotide acetate) Prefilled Syringe
(Atom ID: 6821493)
SYPrescribable
Synonym (SY):
0.2 mL Somatuline 300 mg/ML Prefilled Syringe
(Atom ID: 12983814)
PSNPrescribable
Prescribable Name (PSN):
Somatuline Depot 60 mg in 0.2 mL Prefilled Syringe
(Atom ID: 7235993)
SYPrescribable
Synonym (SY):
Somatuline Depot 60 mg per 0.2 mL Prefilled Syringe
(Atom ID: 2989797)
Patient Education
Lanreotide Injection
Lanreotide injection is used to treat people with acromegaly (condition in which the body produces too much growth hormone, causing enlargement of the hands, feet, and facial features; joint pain; and other symptoms) who have not successfully, or cannot be treated with surgery or radiation. Lanreotide injection is also used to treat people with neuroendocrine tumors in the gastrointestinal (GI) tract or the pancreas (GEP-NETs) that have spread or cannot be removed by surgery. Lanreotide injection is in a class of medications called somatostatin agonists. It works by decreasing the amounts of certain natural substances produced by the body.
[Learn More]
* Please review the disclaimer below.